Ranbaxy to acquire more firms despite changed ownership

Pharmaceutical major Ranbaxy Laboratories, in which Japan’s Daiichi Sankyo will acquire the majority stake, has said it would continue to pursue acquisitions despite the change in ownership.

“We will continue to make acquisitions. As a company, we would continue to grow and I think we need to separate ownership and management. Management of the company will remain same,” Ranbaxy CEO and MD Malvinder Mohan Singh said in an interview to a news channel ‘Sahara Samaya Network’.

He was responding to an query whether the acquisition of the company by Japanese firm Daiichi Sankyo would affect the companies working in future.